Skip to main content

Compare Stocks

Date Range: 

 Enanta PharmaceuticalsPhibro Animal HealthArcturus TherapeuticsAkero TherapeuticsESSA Pharma
SymbolNASDAQ:ENTANASDAQ:PAHCNASDAQ:ARCTNASDAQ:AKRONASDAQ:EPIX
Price Information
Current Price$48.20$27.97$30.82$27.16$29.75
52 Week RangeHoldSellHoldBuyBuy
MarketRank™
Overall Score1.41.61.61.71.4
Analysis Score3.10.53.14.51.5
Community Score2.32.22.62.43.1
Dividend Score0.02.50.00.00.0
Ownership Score1.71.71.71.72.5
Earnings & Valuation Score0.01.30.60.00.0
Analyst Ratings
Consensus RecommendationHoldSellHoldBuyBuy
Consensus Price Target$65.29$22.00$68.58$57.29$28.80
% Upside from Price Target35.45% upside-21.34% downside122.53% upside110.92% upside-3.19% downside
Trade Information
Market Cap$999.85 million$1.14 billion$756.70 million$968.00 million$993.13 million
Beta0.540.463.010.581.96
Average Volume140,581138,3041,055,610274,728331,182
Sales & Book Value
Annual Revenue$122.47 million$800.40 million$20.79 millionN/AN/A
Price / Sales7.951.4239.02N/AN/A
CashflowN/A$2.52 per shareN/AN/AN/A
Price / CashN/A11.10N/AN/AN/A
Book Value$22.70 per share$4.65 per share$1.70 per share$4.51 per share$2.47 per share
Price / Book2.126.0218.13N/AN/A
Profitability
Net Income$-36,170,000.00$33.55 million$-25,990,000.00$-43,760,000.00$-23,440,000.00
EPS($0.89)$1.08($2.15)($2.90)($1.04)
Trailing P/E RatioN/A26.39N/AN/AN/A
Forward P/E RatioN/A24.75N/AN/AN/A
P/E GrowthN/A2.00N/AN/AN/A
Net Margins-29.53%5.37%-506.70%N/AN/A
Return on Equity (ROE)-3.75%23.70%-52.32%-40.84%-46.31%
Return on Assets (ROA)-3.53%5.99%-33.21%-38.33%-45.08%
Dividend
Annual PayoutN/A$0.48N/AN/AN/A
Dividend YieldN/A1.72%N/AN/AN/A
Three-Year Dividend GrowthN/A20.00%N/AN/AN/A
Payout RatioN/A44.44%N/AN/AN/A
Years of Consecutive Dividend GrowthN/A1 YearsN/AN/AN/A
Debt
Debt-to-Equity RatioN/A1.97%0.06%N/AN/A
Current Ratio18.08%2.88%11.21%24.81%66.75%
Quick Ratio18.08%1.61%11.21%24.81%66.75%
Ownership Information
Institutional Ownership Percentage90.78%50.32%74.33%83.49%63.37%
Insider Ownership Percentage10.93%50.05%12.60%7.09%N/A
Miscellaneous
Employees1411,7001182125
Shares Outstanding20.20 million40.50 million26.32 million34.83 million33.78 million
Next Earnings Date8/3/2021 (Estimated)8/25/2021 (Estimated)8/9/2021 (Estimated)8/11/2021 (Estimated)8/5/2021 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableNot Optionable
SourceHeadline
ESSA Pharma (NASDAQ:EPIX) Shares Gap Up to $27.15ESSA Pharma (NASDAQ:EPIX) Shares Gap Up to $27.15
americanbankingnews.com - May 17 at 11:00 AM
 Brokerages Expect ESSA Pharma Inc. (NASDAQ:EPIX) to Post -$0.23 Earnings Per Share Brokerages Expect ESSA Pharma Inc. (NASDAQ:EPIX) to Post -$0.23 Earnings Per Share
americanbankingnews.com - May 9 at 1:05 AM
ESSA Pharma (NASDAQ:EPIX) Posts Quarterly  Earnings Results, Misses Expectations By $0.15 EPSESSA Pharma (NASDAQ:EPIX) Posts Quarterly Earnings Results, Misses Expectations By $0.15 EPS
americanbankingnews.com - May 8 at 10:06 PM
ESSA Pharma reports Q1 resultsESSA Pharma reports Q1 results
seekingalpha.com - May 7 at 3:05 PM
ESSA Pharma: Fiscal Q2 Earnings SnapshotESSA Pharma: Fiscal Q2 Earnings Snapshot
apnews.com - May 6 at 8:08 AM
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021
finance.yahoo.com - May 6 at 8:08 AM
ESSA Pharma (NASDAQ:EPIX) Shares Gap Down to $30.24ESSA Pharma (NASDAQ:EPIX) Shares Gap Down to $30.24
americanbankingnews.com - May 3 at 1:36 PM
ESSA Pharma to Present at the Bloom Burton & Co. Healthcare Investor ConferenceESSA Pharma to Present at the Bloom Burton & Co. Healthcare Investor Conference
finance.yahoo.com - April 14 at 10:54 AM
ESSA Pharma Inc (EPIX)ESSA Pharma Inc (EPIX)
investing.com - April 12 at 12:07 AM
ESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Association of Cancer Research (AACR) Annual MeetingESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Association of Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 10 at 12:55 PM
ESSA Pharma to Present at Upcoming March Investor ConferencesESSA Pharma to Present at Upcoming March Investor Conferences
apnews.com - February 25 at 7:31 PM
ESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate CancerESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer
finance.yahoo.com - February 25 at 9:30 AM
ESSA Pharma Announces Closing of $130 Million Public Offering of Common StockESSA Pharma Announces Closing of $130 Million Public Offering of Common Stock
stockhouse.com - February 22 at 2:32 PM
EPIX: Encouraging Initial Clinical Data for EPI-7386…EPIX: Encouraging Initial Clinical Data for EPI-7386…
finance.yahoo.com - February 12 at 3:10 PM
HC Wainwright & Co. Maintains Buy on ESSA Pharma, Raises Price Target to $36HC Wainwright & Co. Maintains Buy on ESSA Pharma, Raises Price Target to $36
benzinga.com - February 12 at 12:13 AM
ESSA Pharmas Interim EPI-7386 Data Shows Continuous Antigen Decline In Early-Stage Prostate Cancer StudyESSA Pharma's Interim EPI-7386 Data Shows Continuous Antigen Decline In Early-Stage Prostate Cancer Study
finance.yahoo.com - February 11 at 2:12 PM
Why ESSA Pharma, AnaptysBio And More Are Moving TodayWhy ESSA Pharma, AnaptysBio And More Are Moving Today
benzinga.com - February 11 at 12:51 PM
Statement by the Prime Minister on the death of Christopher PlummerStatement by the Prime Minister on the death of Christopher Plummer
finance.yahoo.com - February 5 at 6:11 PM
ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate CancerESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer
finance.yahoo.com - January 13 at 9:15 AM
Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative | MorningstarPfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative | Morningstar
morningstar.com - January 12 at 3:06 PM
Pfizer Invests $120 Million in Biotechnology Innovation Through Pfizer Breakthrough Growth InitiativePfizer Invests $120 Million in Biotechnology Innovation Through Pfizer Breakthrough Growth Initiative
miragenews.com - January 12 at 3:06 PM
Media Advisory -  Aviation Expert Lawyer Rod Winsor Available to Answer Compensation Questions for Families of Ukraine International Airline VictimsMedia Advisory - Aviation Expert Lawyer Rod Winsor Available to Answer Compensation Questions for Families of Ukraine International Airline Victims
finance.yahoo.com - January 8 at 3:50 PM
EPIX: Clinical Data for EPI-7386 in 2021…EPIX: Clinical Data for EPI-7386 in 2021…
finance.yahoo.com - December 17 at 2:25 PM
Is EPIX A Good Stock To Buy Now?Is EPIX A Good Stock To Buy Now?
finance.yahoo.com - December 15 at 11:23 PM
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020
finance.yahoo.com - December 15 at 6:23 PM
DateCompanyBrokerageAction
2/9/2021Enanta PharmaceuticalsRoyal Bank of CanadaBoost Price Target
1/29/2021Enanta PharmaceuticalsJPMorgan Chase & Co.Upgrade
11/23/2020Enanta PharmaceuticalsEvercore ISIInitiated Coverage
10/26/2020Enanta PharmaceuticalsRoth CapitalBoost Price Target
9/23/2020Enanta PharmaceuticalsOppenheimerReiterated Rating
8/25/2020Enanta PharmaceuticalsPiper SandlerInitiated Coverage
7/27/2020Enanta PharmaceuticalsJMP SecuritiesUpgrade
3/17/2020Enanta PharmaceuticalsRobert W. BairdUpgrade
9/18/2019Enanta PharmaceuticalsBerenberg BankSet Price Target
5/24/2019Enanta PharmaceuticalsWolfe ResearchInitiated Coverage
8/8/2018Enanta PharmaceuticalsUBS GroupDowngrade
5/13/2021Phibro Animal HealthMorgan StanleyBoost Price Target
5/8/2020Phibro Animal HealthCredit Suisse GroupLower Price Target
3/31/2020Phibro Animal HealthG.ResearchUpgrade
2/6/2020Phibro Animal HealthGabelliDowngrade
1/28/2020Phibro Animal HealthBarclaysUpgrade
8/29/2019Phibro Animal HealthBank of AmericaLower Price Target
5/23/2019Phibro Animal HealthGuggenheimInitiated Coverage
5/12/2021Arcturus TherapeuticsB. RileyReiterated Rating
1/7/2021Arcturus TherapeuticsWells Fargo & CompanyInitiated Coverage
12/29/2020Arcturus TherapeuticsHC WainwrightDowngrade
12/29/2020Arcturus TherapeuticsRaymond JamesDowngrade
12/14/2020Arcturus TherapeuticsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
12/14/2020Arcturus TherapeuticsSmith Barney CitigroupBoost Price Target
8/11/2020Arcturus TherapeuticsBrookline Capital ManagementReiterated Rating
3/24/2021Akero TherapeuticsCanaccord GenuityLower Price Target
3/23/2021Akero TherapeuticsJefferies Financial GroupReiterated Rating
3/23/2021Akero TherapeuticsChardan CapitalBoost Price Target
2/12/2021ESSA PharmaBloom BurtonReiterated Rating
(Data available from 5/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.